In men with locally advanced prostate cancer, persistent rectal dysfunction did not differ by treatment arm, including 6 versus 18 months of leuprorelin.
In plain wordsIn men with prostate cancer, persistent rectal dysfunction did not differ between treatment arms, including shorter and longer leuprorelin treatment.
- Peptide
- Leuprolide
- Outcome
- No significant changePersistent rectal dysfunction by leuprorelin duration
- Study
n = 1,071
- Comparator
- 6 months of leuprorelin
- Analysis
- Secondary
- Outcome group
- Adverse events · Gastrointestinal
- Studied dose
- Dose not stated · intramuscular · 6 months, or 6 months followed by 12 months (18 months total)As given in this study (human).
Source sentences
No persistent differences in rectal or urinary dysfunction were attributable to treatment arm or to increasing EBRT dose.
3 context sentences(design, population, supporting numbers)
Using a 2×2 factorial trial design men with locally advanced PC were randomly allocated 6 months i.m. leuprorelin prior to radiotherapy either alone or followed by 12 months i.m. leuprorelin.
These two groups received 18 months i.v. zoledronic acid (Z) commencing at randomisation or no further treatment.
Prevalence rates of rectal and urinary dysfunctional symptoms were compared at baseline, the end of RT, 18 and 36 months according to treatment arm, dose and technique using multiple regression models.